IDEAS home Printed from https://ideas.repec.org/a/taf/ijecbs/v33y2026i2p191-203.html

The Generic Exclusivity Period and the Market Life of Drugs

Author

Listed:
  • Keith M. Drake

Abstract

Generic drug sellers are relied on to challenge brand drug patents, but invalidation allows other sellers to enter. The 180-day exclusivity period, awarded to the first challenger of a brand drug’s patent(s), was created to address this potential free-rider problem. The exclusivity period incentivizes challenges but also delays entry by later-filing firms so could harm competition overall. This paper examines whether a drug’s market life (time between brand and generic entry) is longer when the value of the exclusivity period is diminished, which happens when it is shared (by firms filing simultaneously) or forfeited. Among 141 drugs with a new molecule experiencing generic entry during 2015–2025, the average market life was over three years shorter when the exclusivity period was shared and unrelated to forfeiture, even after controlling for drug and patent characteristics. These results challenge the notion that a lucrative exclusivity period is necessary to encourage drug patent challenges.

Suggested Citation

  • Keith M. Drake, 2026. "The Generic Exclusivity Period and the Market Life of Drugs," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 33(2), pages 191-203, May.
    • Handle: RePEc:taf:ijecbs:v:33:y:2026:i:2:p:191-203
    DOI: 10.1080/13571516.2026.2621414
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1080/13571516.2026.2621414
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1080/13571516.2026.2621414?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to

    for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:taf:ijecbs:v:33:y:2026:i:2:p:191-203. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Chris Longhurst (email available below). General contact details of provider: http://www.tandfonline.com/CIJB20 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.